Eltrombopag Olamine is an orally active thrombopoietin receptor agonist used to raise platelet counts in chronic immune thrombocytopenia, severe aplastic anaemia and hepatitis C-associated thrombocytopenia. Simson Pharma's Eltrombopag Olamine reference standard and impurities support stability-indicating method development for this haematology therapy.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Eltrombopag Olamine Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.